SC 79 |
Catalog No.GC11645
One-Click Copy Product Info
|
SC 79 is a specific, blood-brain barrier-permeable Akt agonist.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 305834-79-1
Sample solution is provided at 25 µL, 10mM.
SC 79 is a specific, blood-brain barrier-permeable Akt agonist[1]. SC 79 specifically binds to the PH domain of Akt, activates cytosolic Akt, while inhibiting Akt translocation to the plasma membrane[2]. SC 79 has shown research utility in the fields of neuroprotection, ischemia-reperfusion injury, and apoptosis, and has demonstrated protective effects in animal models of stroke and liver injury[3,4].
In vitro, SC 79 (4μg/mL) pretreatment of HepG2 cells for 30min, followed by co-treatment with TNF-α (0-16ng/mL) for 24h, significantly increased cell viability and reduced TUNEL-positive apoptotic cells[5]. SC 79 (1-10μg/mL) treatment of ARPE-19 cells for 1h dose-dependently induced Akt phosphorylation (p-Akt Ser473) activation[6].
In vivo, SC 79 (10mg/kg) pretreatment of C57BL/6 mice via intraperitoneal injection for 0.5h, followed by administration of D-galactosamine (400mg/kg) and lipopolysaccharide (LPS, 60μg/kg) to induce acute liver injury, significantly reduced hepatic caspase-3/7 activities in mice[5]. SC 79 (10mg/kg) pretreatment of C57BL/6 mice via intraperitoneal injection for 0.5h, followed by administration of a lethal dose of anti-Fas Jo2 to induce acute liver failure, increased the 12h survival rate of mice from 0% to 35%, with no additional mortality observed through the end of the 2-month observation period[7].
References:
[1] Zhu J, Wu Y, Wu D, et al. SC 79, a novel Akt activator, protects dopaminergic neuronal cells from MPP+ and rotenone[J]. Molecular and cellular biochemistry, 2019, 461(1): 81-89.
[2] Jo H, Mondal S, Tan D, et al. Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death[J]. Proceedings of the National Academy of Sciences, 2012, 109(26): 10581-10586.
[3] Luan Q, Pan L, He D, et al. SC 79, the AKT activator protects cerebral ischemia in a rat model of ischemia/reperfusion injury[J]. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 2018, 24: 5391.
[4] Xu Y, Gao Y W, Yang Y. SC 79 protects dopaminergic neurons from oxidative stress[J]. Oncotarget, 2017, 9(16): 12639.
[5] Jing Z T, Liu W, Xue C R, et al. AKT activator SC 79 protects hepatocytes from TNF-α-mediated apoptosis and alleviates d-Gal/LPS-induced liver injury[J]. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2019, 316(3): G387-G396.
[6] Gong Y, Huang W, Li K, et al. SC 79 protects retinal pigment epithelium cells from UV radiation via activating Akt-Nrf2 signaling[J]. Oncotarget, 2016, 7(37): 60123.
[7] Liu W, Jing Z T, Wu S X, et al. A novel AKT activator, SC 79, prevents acute hepatic failure induced by Fas-mediated apoptosis of hepatocytes[J]. The American journal of pathology, 2018, 188(5): 1171-1182.
| Cell experiment [1]: | |
|
Cell lines |
ARPE-19 cells |
|
Preparation Method |
ARPE-19 cells were treated with applied concentration of SC 79 (0.1-10μg/mL) for 1h, p-Akt (Ser-473) and Akt1 expression was tested by Western blot. |
|
Reaction Conditions |
0.1, 1, 5, and 10μg/mL; 1h |
|
Applications |
Treatment with SC 79 induces Akt phosphorylation (p-Akt Ser-473) activation in a dose-dependent manner. |
| Animal experiment [2]: | |
|
Animal models |
C57BL/6 mice |
|
Preparation Method |
C57BL/6 mice were pretreated with SC 79 (10mg/kg; i.p.) for 0.5h, then administered D-galactosamine (400mg/kg) and LPS (60μg/kg). Liver caspase-3/7 activities were measured at 12h after D-Gal/LPS injection using a caspase-3/7 assay kit. |
|
Dosage form |
10mg/kg; i.p. |
|
Applications |
Pretreatment with SC 79 significantly reduces intrahepatic caspase-3/7 activity in mice. |
References: [1] Gong Y, Huang W, Li K, et al. SC 79 protects retinal pigment epithelium cells from UV radiation via activating Akt-Nrf2 signaling[J]. Oncotarget, 2016, 7(37): 60123. [2] Jing Z T, Liu W, Xue C R, et al. AKT activator SC 79 protects hepatocytes from TNF-α-mediated apoptosis and alleviates d-Gal/LPS-induced liver injury[J]. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2019, 316(3): G387-G396. | |
| Cas No. | 305834-79-1 | SDF | |
| Chemical Name | ethyl 2-amino-6-chloro-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate | ||
| Canonical SMILES | CCOC(C(C(C(C(OCC)=O)=C1N)C2=C(O1)C=CC(Cl)=C2)C#N)=O | ||
| Formula | C17H17ClN2O5 | M.Wt | 364.78 |
| Solubility | ≥ 36.5mg/mL in DMSO | Storage | Store at -20°C,unstable in solution, ready to use. |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7414 mL | 13.7069 mL | 27.4138 mL |
| 5 mM | 548.3 μL | 2.7414 mL | 5.4828 mL |
| 10 mM | 274.1 μL | 1.3707 mL | 2.7414 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
-
Related Biological Data
Activation of PFK1 and PFKFB3 is due to phosphorylation of AKT and AMPK. (F) Representative images of ARS and ALP staining in MC3T3-E1 cells after treatment with SC79 and PFK15.
MK-2206 dihydrochloride (GC16304) and SC79 (GC11645) were obtained from GLPBIO.
Clin Transl Med 13.9 (2023): e1369. PMID: 37649137 IF: 10.6002 -
Related Biological Data
SC79 partially rescued the inhibitory effect of proliferation and migration caused by the knockdown of HRL-SC. a, b Western blot analysis showed that SC79 increased expression of p-AKT.
The medium was replaced with the medium containing 5 μg/mL of SC79 (10 μM, GlpBio) in AKT activation experiments.
Stem Cell Res Ther 13.1 (2022): 1-16. PMID: 35765088 IF: 7.4996 -
Related Biological Data
Melatonin inhibits the AKT/mTOR signaling to reduce autophagy and the expression of fibrotic proteins in HSFs. (E) Treatment with SC79 to activate the AKT/mTOR signaling rescued the melatonin-decreased AKT/mTOR signaling and fibrotic protein expression in HSFs.
HSFs were treated with vehicle (DMSO) or 200 μM melatonin and/or 10 μM SC79 (Glpbio) for 24 h.
Bba-Mol Basis Dis (2023): 166887. PMID: 37739092 IF: 6.2001 -
Related Biological Data
CST1 enhances SERPINB2 expression via AKT signaling pathway in bronchial epithelial cells. (C) SC-79 has a positive effect on SERPINB2 expression (n = 2).
BEAS-2B cells were stimulated with or without cytokines IL-4, IL-13, and IL-17A,17 stimulated with or without house dust mite, treated with or without E64d, induced with SC-79 (4 μg/mL, AKT activator; GlpBio) or MK2206USA).
Allergy Asthma Immun 15.3 (2023): 374. PMID: 37075800 IF: 4.4 -
Related Biological Data
Rescue experiments were conducted to verify the mechanism of TOP2A regulating OC cell behavior. (a-c) after SC79 treatment of cells in the SH-TOP2A group, WB results suggested that the levels of p-AKT/AKT and p-mTOR/mTOR were increased.
Lyophilized SC79 (GC11645, Glpbio), an activator of AKT, was resuspended in 500 μL of DMSO at 20 μg/μL, followed by storage at −20°C for later use.
Cancer Biol Ther 25.1 (2024): 2325126. PMID: 38445610 IF: 3.5999
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)